Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Eli Lilly (NYSE:LLY) has successfully completed its acquisition of Verve Therapeutics (NASDAQ:VERV), a Boston-based clinical-stage biotechnology company specializing in genetic medicines for cardiovascular disease. The strategic acquisition aims to revolutionize cardiovascular treatment through the development of one-time genetic therapies that could provide lifelong cardiovascular risk reduction.
Led by Ruth Gimeno, Lilly's group vice president of Diabetes and Metabolic Research and Development, this acquisition represents a significant step towards expanding Lilly's presence in the cardiovascular therapeutic space and advancing innovative genetic medicine solutions.
Eli Lilly (NYSE:LLY) ha completato con successo l'acquisizione di Verve Therapeutics (NASDAQ:VERV), una società biotecnologica con sede a Boston e in fase clinica, specializzata in terapie genetiche per le malattie cardiovascolari. Questa acquisizione strategica punta a rivoluzionare il trattamento cardiovascolare attraverso lo sviluppo di terapie genetiche monodose che potrebbero garantire una riduzione del rischio cardiovascolare a vita.
Guidata da Ruth Gimeno, vicepresidente del gruppo per la Ricerca e Sviluppo in Diabete e Metabolismo di Lilly, questa acquisizione rappresenta un passo importante per ampliare la presenza di Lilly nel campo terapeutico cardiovascolare e promuovere soluzioni innovative basate sulla medicina genetica.
Eli Lilly (NYSE:LLY) ha completado con éxito la adquisición de Verve Therapeutics (NASDAQ:VERV), una empresa biotecnológica en etapa clínica con sede en Boston, especializada en medicamentos genéticos para enfermedades cardiovasculares. Esta adquisición estratégica busca revolucionar el tratamiento cardiovascular mediante el desarrollo de terapias genéticas de una sola vez que podrían ofrecer una reducción del riesgo cardiovascular de por vida.
Bajo la dirección de Ruth Gimeno, vicepresidenta del grupo de Investigación y Desarrollo en Diabetes y Metabolismo de Lilly, esta adquisición representa un paso significativo para ampliar la presencia de Lilly en el ámbito terapéutico cardiovascular y avanzar en soluciones innovadoras de medicina genética.
Eli Lilly (NYSE:LLY)는 보스턴에 본사를 둔 임상 단계의 생명공학 회사인 Verve Therapeutics (NASDAQ:VERV)의 인수를 성공적으로 완료했습니다. 이 회사는 심혈관 질환을 위한 유전자 치료제 개발에 특화되어 있습니다. 이번 전략적 인수는 일회성 유전자 치료제를 개발하여 평생 심혈관 위험 감소를 제공하는 혁신적인 심혈관 치료를 목표로 합니다.
루스 히메노(Lilly 당뇨 및 대사 연구개발 그룹 부사장)가 이끄는 이번 인수는 Lilly가 심혈관 치료 분야에서 입지를 확장하고 혁신적인 유전자 치료 솔루션을 발전시키는 중요한 단계입니다.
Eli Lilly (NYSE:LLY) a finalisé avec succès l'acquisition de Verve Therapeutics (NASDAQ:VERV), une société biotechnologique en phase clinique basée à Boston, spécialisée dans les médicaments génétiques pour les maladies cardiovasculaires. Cette acquisition stratégique vise à révolutionner le traitement cardiovasculaire grâce au développement de thérapies génétiques à dose unique pouvant offrir une réduction du risque cardiovasculaire à vie.
Dirigée par Ruth Gimeno, vice-présidente du groupe en charge de la recherche et du développement en diabète et métabolisme chez Lilly, cette acquisition représente une étape importante pour renforcer la présence de Lilly dans le domaine thérapeutique cardiovasculaire et faire progresser des solutions innovantes en médecine génétique.
Eli Lilly (NYSE:LLY) hat die Übernahme von Verve Therapeutics (NASDAQ:VERV) erfolgreich abgeschlossen, einem biotechnologischen Unternehmen mit Sitz in Boston, das sich in der klinischen Phase befindet und auf genetische Medikamente für Herz-Kreislauf-Erkrankungen spezialisiert ist. Die strategische Übernahme zielt darauf ab, die Herz-Kreislauf-Behandlung durch die Entwicklung einmaliger Gentherapien zu revolutionieren, die eine lebenslange Reduzierung des kardiovaskulären Risikos bieten könnten.
Unter der Leitung von Ruth Gimeno, Lillys Gruppen-Vizepräsidentin für Diabetes- und Stoffwechselforschung und -entwicklung, stellt diese Übernahme einen bedeutenden Schritt dar, um Lillys Präsenz im Bereich der Herz-Kreislauf-Therapie zu erweitern und innovative genetische Medizinlösungen voranzutreiben.
- Strategic expansion into genetic medicines for cardiovascular disease
- Potential to develop revolutionary one-time treatments for cardiovascular conditions
- Access to Verve's clinical-stage pipeline and expertise in genetic medicines
- Enhancement of Lilly's cardiometabolic disease portfolio
- Integration risks associated with merging research and development teams
- Clinical development uncertainties with genetic medicine programs
- Potential regulatory challenges for novel genetic treatments
"This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment," said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. "We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines for cardiometabolic disease."
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding Lilly's acquisition of Verve, regarding prospective benefits of the acquisition and Verve's gene editing programs for cardiovascular disease, regarding Verve's product candidates and ongoing clinical and preclinical development, and regarding Lilly's development of programs for cardiovascular disease and advancement of cardiometabolic health medicines. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to drug research, development and commercialization, Lilly's evaluation of the accounting treatment of the acquisition and its potential impact on its financial results and financial guidance, regulatory changes and developments, the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, risks that the acquisition disrupts current plans and operations or adversely affect employee retention, and any legal proceedings that have been or may be instituted related to the acquisition. Actual results could differ materially due to various factors, risks and uncertainties. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that product candidates will be approved on anticipated timelines or at all, that any products, if approved, will be commercially successful, that all or any of the contingent consideration will become payable on the terms described herein or at all, that Lilly's financial results will be consistent with its expected 2025 guidance or that Lilly can reliably predict the impact of the acquisition on its financial results or financial guidance. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the
Refer to: | Ashley Hennessey; gentry_ashley_jo@lilly.com; 317-416-4363 (Media) |
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-completes-acquisition-of-verve-therapeutics-to-advance-one-time-treatments-for-people-with-high-cardiovascular-risk-302513948.html
SOURCE Eli Lilly and Company